Anti-Radiation Drugs Market Size and Trends
Global Anti-Radiation Drugs Market size is expected to be valued at US$ 587.4 Mn in 2023, and is expected to reach US$ 931 Mn by 2030, exhibiting a compound annual growth rate (CAGR) of 6.8% from 2023 to 2030.
Global Anti-Radiation Drugs Market- Trends
- Accelerated research on radiomitigators showing delayed efficacy: Most investigational anti-radiation agents demonstrated efficacy when administered before exposure. However, in the event of a surprise nuclear detonation or accident, pretreatment is not possible. There is a growing focus on radiomitigators that can be provided after exposure and still provide meaningful protection by mitigating delayed effects. Research is focused on drugs that can suppress prolonged inflammation and oxidative stress.
- Shift towards natural and plant-based radio-protectants: Synthetic radioprotective compounds often have undesirable side effects. Hence, there is increasing research on plant-derived molecules like flavonoids, antioxidants and polysaccharides that can enhance the resistance of normal tissues to radiation. Compounds derived from ginseng, orientin, bromelain and many other botanicals are being evaluated as natural radioprotective agents. The goal is to develop effective and safe agents leveraging traditional medicine. For instance, Journal of pharmacy & biological sciences 2021, showed that natural herbal products are nontoxic with proven therapeutic benefits and have long been used to treat various diseases.
- Emergence of system biology and OMICS approaches: Conventional pharmacological research is being combined with systems biology and OMICS techniques like transcriptomics, proteomics and metabolomics to identify novel molecular targets and biomarkers for anti-radiation drug discovery. Such interdisciplinary approaches are providing unprecedented insight into mechanisms of radiation injury and action of radioprotective agents in humans. This can support efficient development of effective countermeasures.
- Selective protection of radiosensitive organs: Rather than systemic protection, there is rising focus on developing drugs that can selectively shield organs most susceptible to acute and delayed effects of radiation such as bone marrow, gastrointestinal tract, lungs, skin and eyes. For instance, oral mucosal radioprotectant gel is being developed to prevent mucositis during head & neck radiation therapy. Such targeted organ protection can improve patient outcomes.
U.S.: 
U.K. : 
India : 
